DelMar Announces Approval of Merger by Stockholders

DelMar Announces Approval of Merger by

SAN DIEGO, August 17, 2020 - DelMar Pharmaceuticals,

Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that all proposals related to the proposed

merger between DelMar and Adgero were approved by DelMar's stockholders at a special meeting held on August 14, 2020.

The holders of a majority of the outstanding shares of common stock of Adgero have also issued their written consent approving

the merger. The proposed merger remains subject to further customary closing conditions. DelMar expects the closing of the merger

to occur in August 2020.

Upon closing of the transaction, the combined company will change

its name to "Kintara Therapeutics, Inc." and it is anticipated that the shares will commence trading on the Nasdaq

Capital Market under the ticker symbol "KTRA."

The final voting results for DelMar's special meeting

of stockholders will be filed with the Securities and Exchange Commission in a Form 8-K.

Located in San Diego, California, DelMar

is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options.

By focusing on understanding tumor biology and mechanisms of treatment resistance, DelMar identifies biomarkers to personalize

new therapies in indications where patients are failing, or are unable to tolerate, standard-of-care treatments.

DelMar's current pipeline is

based around VAL-083, a "first-in-class", small-molecule chemotherapeutic with a novel mechanism

of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other

solid tumors (e.g. NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI).

Based on DelMar's internal research programs and these prior NCI-sponsored clinical studies, DelMar is conducting

clinical trials to support the development and commercialization of VAL-083 to solve significant unmet medical needs.

VAL-083 is being studied in two

collaborator-supported, biomarker-driven Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance

represents a significant unmet medical need in the treatment of GBM. In addition, DelMar has announced the allowance of a separate

IND for VAL-083 as a potential treatment for platinum-resistant ovarian cancer.

Adgero Biopharmaceuticals Holdings,

Inc. is a biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy

("PDT") platform that holds promise as a localized cutaneous or visceral tumor treatment. Additionally, PDT has immune

activating properties and has potential therapeutic utility in oncology as a combination therapy in conjunction with immunotherapies.

It is also being investigated in the cardiovascular setting as treatment for hemodialysis access failure. Adgero's lead product

candidate, REM-001 therapy, has been previously studied in four Phase 2/3 clinical trials in patients with cutaneous

metastatic breast cancer (CMBC), who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy

to date of 80% complete responses of CMBC evaluable lesions and with an existing robust safety database of approximately 1,100

patients across multiple indications, Adgero is currently focused on advancing the REM-001 program to late stage pivotal

Forward-Looking Statements

release contains forward-looking statements based upon DelMar's and Adgero's current expectations. This

communication contains "forward-looking statements" within the meaning of the Private Securities Litigation

Reform Act of 1995. Forward-looking statements are identified by terminology such as "may," "should,"

"expects," "plans," "anticipates," "could," "intends,"

"target," "projects," "contemplates," "believes," "estimates,"

"predicts," "potential" or "continue" or the negative of these terms or other similar

words. These statements are only predictions. DelMar and Adgero have based these forward-looking statements largely on their

then-current expectations and projections about future events, as well as the beliefs and assumptions of management.

Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances

that are beyond each of DelMar's and Adgero's control, and actual results could differ materially from those

stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) risks

associated with the timing of the closing of the proposed merger transaction, including the risks that a condition to closing

would not be satisfied within the expected timeframe or at all or that the closing of the proposed merger transaction will

not occur; (ii) the outcome of any legal proceedings that may be instituted against the parties and others related to

the merger agreement; (iii) the occurrence of any event, change or other circumstance or condition that could give rise

to the termination of the merger agreement, (iv) unanticipated difficulties or expenditures relating to the proposed

merger transaction, the response of business partners and competitors to the announcement of the proposed merger transaction,

and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed merger

transaction; (v) whether the combined business of Adgero and DelMar will be successful, and (vi) those risks

detailed in DelMar's most recent Annual Report on Form 10-K and subsequent reports filed with the SEC, as

well as other documents that may be filed by DelMar from time to time with the SEC. Accordingly, you should not rely upon

forward-looking statements as predictions of future events. Neither DelMar nor Adgero can assure you that the events and

circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ

materially from those projected in the forward-looking statements. The forward-looking statements made in this communication

relate only to events as of the date on which the statements are made. Except as required by applicable law or regulation,

DelMar and Adgero undertake no obligation to update any forward-looking statement to reflect events or circumstances after

the date on which the statement is made or to reflect the occurrence of unanticipated events. Investors should not assume

that any lack of update to a previously issued "forward-looking statement" constitutes a reaffirmation of that

Additional Information and Where

This press release is for informational

purposes only and does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or

a solicitation of any vote or approval. This press release relates to the proposed merger of DelMar and Adgero. In connection with

the proposed merger, DelMar filed a registration statement on Form S-4 (No. 333-239215), which includes the joint proxy statement/prospectus.

The registration statement was declared effective by the SEC on July 2, 2020, and DelMar commenced mailing the Joint Proxy Statement/Prospectus

on or about July 2, 2020. DelMar will file other documents regarding the proposed merger transaction with the U.S. Securities and

Exchange Commission (the "SEC"). No offering of securities shall be made, except by means of a prospectus meeting the

requirements of Section 10 of the U.S. Securities Act of 1933, as amended. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ

THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME

AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING

THE PROPOSED MERGER. A definitive proxy statement/prospectus will be sent to DelMar's stockholders. Investors and security

holders will be able to obtain these documents (when available) free of charge from the SEC's website at www.sec.gov. The

documents filed by DelMar with the SEC may also be obtained free of charge from DelMar by requesting them by mail at DelMar Pharmaceuticals,

Inc., 12707 High Bluff Drive, Suite 200, San Diego, CA 92130.

No Offer or Solicitation

This press release shall not constitute

an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction

in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of

any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10

of the Securities Act of 1933, as amended.

Director of Public Relations

Jenene Thomas Communications